The economic burden of hepatitis A, B, and C in South Korea

Changwoo Shon, Hyung Yun Choi, Jae Jun Shim, So Youn Park, Kyung Suk Lee, Seok-Jun Yoon, In Hwan Oh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The prevalence of hepatitis in South Korea is relatively high compared to that in other high-income countries. For this reason, viral hepatitis infection not only affects the population’s health, but also impacts national healthcare costs. This study was performed in order to estimate the individual economic costs of the hepatitis A, B, and C viruses as well as to determine, using nationally representative data, the trends in South Korea with respect to these viruses during the 2008-2011 period. The study found that the prevalence of hepatitis A had decreased, but those of hepatitis B and C had increased overall. The mortality rate of hepatitis C was higher than that of the other two types. The mortality rate of hepatitis B had changed little, whereas that of hepatitis C had risen. The total cost of hepatitis A had decreased, from US $62.2 million to US $45.7 million, although a notable exception occurred in 2009, when the cost was US $126.6 million. Conversely, the total cost of hepatitis B had increased rapidly during the same period, from US $501.4 million to US $607.8 million. Finally, the total cost of hepatitis C had also increased from US $63.9 million to US $90.7 million. The direct costs of hepatitis A, B, and C were estimated to account for approximately 35.5z, 46.6z, and 58.0zof the total, respectively. These findings demonstrate the economic burden associated with hepatitis A, B, and C, and demonstrate the need to establish an effective prevention and management policy for future planning in South Korea.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalJapanese Journal of Infectious Diseases
Volume69
Issue number1
DOIs
Publication statusPublished - 2016 Jan 21

Fingerprint

Republic of Korea
Hepatitis A
Hepatitis C
Hepatitis B
Economics
Costs and Cost Analysis
Hepatitis
Hepatitis A virus
Mortality
Virus Diseases
Hepatitis B virus
Hepacivirus
Health Care Costs
Cross-Sectional Studies
Viruses
Health
Population

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

The economic burden of hepatitis A, B, and C in South Korea. / Shon, Changwoo; Choi, Hyung Yun; Shim, Jae Jun; Park, So Youn; Lee, Kyung Suk; Yoon, Seok-Jun; Oh, In Hwan.

In: Japanese Journal of Infectious Diseases, Vol. 69, No. 1, 21.01.2016, p. 18-27.

Research output: Contribution to journalArticle

Shon, Changwoo ; Choi, Hyung Yun ; Shim, Jae Jun ; Park, So Youn ; Lee, Kyung Suk ; Yoon, Seok-Jun ; Oh, In Hwan. / The economic burden of hepatitis A, B, and C in South Korea. In: Japanese Journal of Infectious Diseases. 2016 ; Vol. 69, No. 1. pp. 18-27.
@article{8aabce6f8b124292b193da4bae83c1fb,
title = "The economic burden of hepatitis A, B, and C in South Korea",
abstract = "The prevalence of hepatitis in South Korea is relatively high compared to that in other high-income countries. For this reason, viral hepatitis infection not only affects the population’s health, but also impacts national healthcare costs. This study was performed in order to estimate the individual economic costs of the hepatitis A, B, and C viruses as well as to determine, using nationally representative data, the trends in South Korea with respect to these viruses during the 2008-2011 period. The study found that the prevalence of hepatitis A had decreased, but those of hepatitis B and C had increased overall. The mortality rate of hepatitis C was higher than that of the other two types. The mortality rate of hepatitis B had changed little, whereas that of hepatitis C had risen. The total cost of hepatitis A had decreased, from US $62.2 million to US $45.7 million, although a notable exception occurred in 2009, when the cost was US $126.6 million. Conversely, the total cost of hepatitis B had increased rapidly during the same period, from US $501.4 million to US $607.8 million. Finally, the total cost of hepatitis C had also increased from US $63.9 million to US $90.7 million. The direct costs of hepatitis A, B, and C were estimated to account for approximately 35.5z, 46.6z, and 58.0zof the total, respectively. These findings demonstrate the economic burden associated with hepatitis A, B, and C, and demonstrate the need to establish an effective prevention and management policy for future planning in South Korea.",
author = "Changwoo Shon and Choi, {Hyung Yun} and Shim, {Jae Jun} and Park, {So Youn} and Lee, {Kyung Suk} and Seok-Jun Yoon and Oh, {In Hwan}",
year = "2016",
month = "1",
day = "21",
doi = "10.7883/yoken.JJID.2014.499",
language = "English",
volume = "69",
pages = "18--27",
journal = "Japanese Journal of Infectious Diseases",
issn = "1344-6304",
publisher = "National Institute of Health",
number = "1",

}

TY - JOUR

T1 - The economic burden of hepatitis A, B, and C in South Korea

AU - Shon, Changwoo

AU - Choi, Hyung Yun

AU - Shim, Jae Jun

AU - Park, So Youn

AU - Lee, Kyung Suk

AU - Yoon, Seok-Jun

AU - Oh, In Hwan

PY - 2016/1/21

Y1 - 2016/1/21

N2 - The prevalence of hepatitis in South Korea is relatively high compared to that in other high-income countries. For this reason, viral hepatitis infection not only affects the population’s health, but also impacts national healthcare costs. This study was performed in order to estimate the individual economic costs of the hepatitis A, B, and C viruses as well as to determine, using nationally representative data, the trends in South Korea with respect to these viruses during the 2008-2011 period. The study found that the prevalence of hepatitis A had decreased, but those of hepatitis B and C had increased overall. The mortality rate of hepatitis C was higher than that of the other two types. The mortality rate of hepatitis B had changed little, whereas that of hepatitis C had risen. The total cost of hepatitis A had decreased, from US $62.2 million to US $45.7 million, although a notable exception occurred in 2009, when the cost was US $126.6 million. Conversely, the total cost of hepatitis B had increased rapidly during the same period, from US $501.4 million to US $607.8 million. Finally, the total cost of hepatitis C had also increased from US $63.9 million to US $90.7 million. The direct costs of hepatitis A, B, and C were estimated to account for approximately 35.5z, 46.6z, and 58.0zof the total, respectively. These findings demonstrate the economic burden associated with hepatitis A, B, and C, and demonstrate the need to establish an effective prevention and management policy for future planning in South Korea.

AB - The prevalence of hepatitis in South Korea is relatively high compared to that in other high-income countries. For this reason, viral hepatitis infection not only affects the population’s health, but also impacts national healthcare costs. This study was performed in order to estimate the individual economic costs of the hepatitis A, B, and C viruses as well as to determine, using nationally representative data, the trends in South Korea with respect to these viruses during the 2008-2011 period. The study found that the prevalence of hepatitis A had decreased, but those of hepatitis B and C had increased overall. The mortality rate of hepatitis C was higher than that of the other two types. The mortality rate of hepatitis B had changed little, whereas that of hepatitis C had risen. The total cost of hepatitis A had decreased, from US $62.2 million to US $45.7 million, although a notable exception occurred in 2009, when the cost was US $126.6 million. Conversely, the total cost of hepatitis B had increased rapidly during the same period, from US $501.4 million to US $607.8 million. Finally, the total cost of hepatitis C had also increased from US $63.9 million to US $90.7 million. The direct costs of hepatitis A, B, and C were estimated to account for approximately 35.5z, 46.6z, and 58.0zof the total, respectively. These findings demonstrate the economic burden associated with hepatitis A, B, and C, and demonstrate the need to establish an effective prevention and management policy for future planning in South Korea.

UR - http://www.scopus.com/inward/record.url?scp=84955112046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955112046&partnerID=8YFLogxK

U2 - 10.7883/yoken.JJID.2014.499

DO - 10.7883/yoken.JJID.2014.499

M3 - Article

C2 - 25971325

AN - SCOPUS:84955112046

VL - 69

SP - 18

EP - 27

JO - Japanese Journal of Infectious Diseases

JF - Japanese Journal of Infectious Diseases

SN - 1344-6304

IS - 1

ER -